KYTX vs XFOR: stock comparison and AI forecast
Kyverna Therapeutics, Inc. (KYTX) and X4 Pharmaceuticals, Inc (XFOR) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
KYTX Kyverna Therapeutics, Inc.
- Market Cap
- $302M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
XFOR X4 Pharmaceuticals, Inc
- Market Cap
- $315M
- P/E Ratio
- 1.5x
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- KYTX and XFOR have similar market capitalizations ($302M and $315M).
- XFOR carries 0.67 times debt per unit of equity, against 0.33 times for KYTX.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | KYTX | XFOR |
|---|---|---|
| Market Cap | $302M | $315M |
| P/E Ratio | – | 1.49x |
| P/B Ratio | 1.82x | 2.27x |
| EPS | $-2.27 | $2.13 |
| Book Value/Share | $2.68 | $1.40 |
| Revenue/Share | – | $0.10 |
Profitability & Margins
| Metric | KYTX | XFOR |
|---|---|---|
| ROE | -92.2% | – |
| ROA | -69.4% | – |
| ROIC | -80.7% | -37.1% |
| Gross Margin | – | 88.0% |
| Operating Margin | – | -812.8% |
| EBT Margin | – | -810.9% |
| Tax Rate | – | -0.0% |
Financial Health
| Metric | KYTX | XFOR |
|---|---|---|
| Current Ratio | 9.06x | 13.22x |
| Quick Ratio | – | 13.21x |
| D/E Ratio | 0.33x | 0.67x |
| Financial Leverage | 1.33x | 1.67x |
| Interest Coverage | -69.0x | -2.9x |
| Working Capital | $184M | $183M |
Cash Flow
| Metric | KYTX | XFOR |
|---|---|---|
| Operating Cash Flow | -$159M | -$76M |
Operational Efficiency
| Metric | KYTX | XFOR |
|---|---|---|
| Asset Turnover | – | 0.04x |
| Receivables Turnover | – | 6.7x |
| Inventory Turnover | – | 12.1x |
| Fixed Assets Turnover | – | 173.5x |
| Days Sales Outstanding | – | 54 days |
| Days Inventory | – | 30 days |
| Payables Period | – | 577 days |
| Cash Conversion Cycle | – | -492 days |
Income Statement
| Metric | KYTX | XFOR |
|---|---|---|
| Total Revenue | – | $10M |
| Operating Income | -$159M | -$80M |
| Net Income | -$153M | – |
| R&D Expense | $115M | $62M |
| Cost of Goods Sold | – | $3M |
Dividend & Shareholder Information
| Metric | KYTX | XFOR |
|---|---|---|
| Shares Outstanding | 62M | 99M |
KYTX vs XFOR: stock comparison and AI forecast
Which is bigger, KYTX or XFOR?
KYTX and XFOR have similar market capitalizations ($302M and $315M).
Which one does Intratio's AI model rank higher, KYTX or XFOR?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.